Nanoparticle-boosted myeloid-derived suppressor cell therapy for immune reprogramming in multiple sclerosis

Area of Science:

• Neuroimmunology
• Translational Medicine
• Drug Delivery Systems

Background:

• Multiple sclerosis (MS) is characterized by immune cell infiltration and chronic inflammation in the central nervous system (CNS).
• Current therapeutic strategies aim to modulate the immune response but often lack targeted delivery to the CNS.

Purpose of the Study:

• To develop and evaluate a novel myeloid-derived suppressor cell (MDSC)-based therapeutic strategy for targeted immune reprogramming in the CNS.
• To assess the efficacy of this strategy in an experimental autoimmune encephalomyelitis (EAE) model of MS.

Main Methods:

• Development of a therapy named CNS Immune Targeting Enabled by MDSCs (CITED), utilizing MDSCs decorated with rapamycin nanoparticles (NPs).
• Evaluation of NP-decorated MDSCs for enhanced immunomodulatory function, CNS trafficking, and NP accumulation.
• Assessment of CITED's therapeutic efficacy in an EAE mouse model, measuring disease progression, motor function, and myelin damage.

Main Results:

• NP decoration enhanced MDSC immunomodulatory capacity and facilitated targeted delivery to inflamed CNS regions.
• CITED treatment significantly reduced disease progression, improved motor function, and minimized myelin damage in the EAE model.
• Mechanistic studies confirmed CITED's ability to inhibit immune cell infiltration, rebalance CD4 T cell phenotypes, and promote anti-inflammatory myeloid cell polarization.

Conclusions:

• The CITED strategy demonstrates robust therapeutic potential for multiple sclerosis by enabling targeted immune restoration within the CNS.
• This approach offers a broadly effective method for modulating both innate and adaptive immune responses in CNS autoimmune diseases.